Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 9/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560918 | 0.78 | TDP1 (0.55) | TDP1MEN1KMT2AMAPTHTT | |
| SCHEMBL17560912 | 0.78 | TDP1 (0.55) | TDP1MEN1KMT2AMAPTHTT | |
| SCHEMBL17560915 | 0.78 | TDP1 (0.55) | TDP1MEN1KMT2AMAPTHTT | |
| SCHEMBL28120583 | 0.76 | SMN1; SMN2 (0.49) | TDP1DRD4DRD2MEN1KMT2A | |
| SCHEMBL19449767 | 0.75 | TDP1 (0.46) | TDP1MEN1KMT2AHTTNPSR1 | |
| SCHEMBL2768439 | 0.73 | TDP1 (0.59) | TDP1ACHEMEN1KMT2AALDH1A1 | |
| SCHEMBL8429957 | 0.73 | TDP1 (0.52) | TDP1MEN1KMT2AHTTNPSR1 | |
| SCHEMBL2769813 | 0.72 | TDP1 (0.41) | TDP1DRD4DRD2MEN1KMT2A | |
| SCHEMBL2787244 | 0.72 | TDP1 (0.41) | TDP1DRD4DRD2MEN1KMT2A | |
| SCHEMBL2770616 | 0.72 | TDP1 (0.46) | TDP1DRD4DRD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643989-B1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-7132421-B2 | CIS-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1643989-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005002575-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20040259867-A1 | CIS-imidazoles | FOTOUHI NADER (US) | 2004-12-23 | — | — | US | disclosed |
| US-20040259867-A1 | CIS-imidazoles | FOTOUHI NADER (US) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259867-A1 | CIS-imidazoles | TP53, MDM2, TP53BP1 | TDP1 1038/4885DRD4 4388/4885DRD2 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.